| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,850 |
4,276 |
$168K |
| 62323 |
|
602 |
415 |
$58K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,778 |
2,006 |
$49K |
| 99152 |
|
2,700 |
1,784 |
$43K |
| 20610 |
|
834 |
574 |
$14K |
| 80305 |
|
4,216 |
2,779 |
$5K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
54 |
37 |
$2K |
| 64483 |
|
15 |
14 |
$2K |
| 77003 |
|
51 |
37 |
$63.97 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
1,905 |
1,263 |
$58.77 |
| J3490 |
Unclassified drugs |
590 |
446 |
$45.34 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
798 |
579 |
$38.07 |
| 99070 |
|
116 |
85 |
$20.00 |
| G9578 |
Documentation of signed opioid treatment agreement at least once during opioid therapy |
936 |
639 |
$0.03 |
| G9562 |
Patients who had a follow-up evaluation conducted at least every three months during opioid therapy |
944 |
643 |
$0.03 |
| 3288F |
|
680 |
436 |
$0.03 |
| G9584 |
Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy |
934 |
635 |
$0.03 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
35 |
30 |
$0.00 |
| G9368 |
At least two orders for high-risk medications from the same drug class not ordered |
159 |
109 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
509 |
368 |
$0.00 |
| G9365 |
One high-risk medication ordered |
106 |
70 |
$0.00 |